Correlation Engine 2.0
Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

Tofacitinib has revolutionized the treatment of numerous dermatological conditions in different age groups. However, evidence for its effectiveness, safety and tolerability in the paediatric population is limited. We performed a literature search, which showed that oral tofacitinib is a reliable option in refractory juvenile dermatomyositis, severe alopecia areata, atopic dermatitis and psoriasis. Topical tofacitinib is an effective option in vitiligo and halo naevus. The risk-benefit ratio should be assessed prior to consideration of this molecule. In this narrative review, we have attempted to present a summary of the evidence of using tofacitinib (oral and topical) in paediatric dermatoses. © 2022 British Association of Dermatologists.


Ishan Agarwal, Maitreyee Panda, Anupam Das. Tofacitinib in paediatric dermatoses: a narrative review. Clinical and experimental dermatology. 2022 Jul;47(7):1256-1264

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 35279865

View Full Text